Feature ArticleBiodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
Graphical Abstract
While cyclic dinucleotides (CDNs; STING agonists) are potent IFN inducing agents, these adjuvants have a narrow therapeutic window partly due to their inability to efficiently bypass the cellular membrane. The net negative charge of CDNs limits their cytosolic bioavailability and interaction with the cytosolic protein STING, necessitating micromolar extracellular concentrations for effective activation. Here, we demonstrate the utilization of biodegradable, cationic polymeric nanoparticles for cytosolic delivery of CDNs to professional antigen presenting cells for log-fold improved adjuvant activity in vitro and in vivo.
Section snippets
Chemicals
All chemicals were of analytical grade and obtained from Sigma Aldrich Chemicals (St Louis, MO, USA). RPMI 1640 medium (Gibco BRL, Grand Island, NY, USA), fluorochrome conjugated antibodies (BD Biosciences, San Jose, CA, USA), MTT Aqueous One cell viability kit (Promega, Madison, WI, USA) were used without modification. Cyclic dinucleotides were provided by Aduro Biotech (Berkeley, CA, USA). QUANTI-blue and THP1-ISG cells were purchased from Invivogen (San Diego, CA, USA). Monocyte isolation
CDNs are potent activators of IRF3 at micromolar doses
Recent publications have shown CDNs to be potent activators of the adaptive immune system via activation of type I IFN and proinflammatory cytokine response leading to potent efficacy in multiple models of established cancer.1 As a result, we selected the CDNs shown in Figure 1, A to act as adjuvant molecules for studies in vitro. ML-RR-CDA is a modified version of cyclic-di-AMP formulated for increased in vivo stability and human STING activation, while RR-CDG was a phosphodiesterase resistant
Discussion
CDNs are highly potent adjuvants that can impact clinical cancer immunotherapy, leading to robust activation of the IRF3 transcription factor through STING, which is capable of triggering tumor regression when activated in the right context.1, 26, 31 With promising pre-clinical results reported to date, CDNs are currently under investigation in the FDA Phase I clinical trials for advanced metastatic solid tumors and lymphomas (NCT02675439) by Aduro Biotech working with Novartis to determine the
Acknowledgment
The authors thank Dr. Kristen Kozielski for the synthesis of polymer PBAE R647 used in the screening study.
References (36)
- et al.
Immune checkpoint blockade: a common denominator approach to cancer therapy
Cancer Cell
(2015) - et al.
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Lancet Oncol
(2016) - et al.
Non-viral gene delivery nanoparticles based on poly(β-amino esters) for treatment of glioblastoma
Biomaterials
(2011) - et al.
Gene delivery nanoparticles specific for human microvasculature and macrovasculature
Nanomedicine
(2012) - et al.
Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma
J Control Release
(2017) - et al.
Quantification of cellular and nuclear uptake rates of polymeric gene delivery nanoparticles and DNA plasmids via flow cytometry
Acta Biomater
(2016) - et al.
Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation
Biomaterials
(2012) - et al.
The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures
Biomaterials
(2010) - et al.
Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity
Cell Rep
(2015) - et al.
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Sci Transl Med
(2015)
Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants
Ther Adv Vaccines
STING is a direct innate immune sensor of cyclic di-GMP
Nature
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
N Engl J Med
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer
Cancer Immunol Res
Nivolumab versus everolimus in advanced renal-cell carcinoma
N Engl J Med
Safety and activity of anti–PD-L1 antibody in patients with advanced cancer
N Engl J Med
Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
J Clin Oncol
Degradable poly(β-amino esters): synthesis, characterization, and self-assembly with plasmid DNA
J Am Chem Soc
Cited by (166)
Reviewing black phosphorus for biomedical and optoelectronic applications
2024, Inorganic Chemistry CommunicationsTargeting STING in cancer: Challenges and emerging opportunities
2023, Biochimica et Biophysica Acta - Reviews on CancerRecent trends in STING modulators: Structures, mechanisms, and therapeutic potential
2023, Drug Discovery Today
Funding support: The authors thank the NIH for support of this research (NIH R01EB016721, R01EB022148, and R01CA195503; Wilmer Core Grant (5P30EY001765); NIH S10 OD016374; NIH R01CA178613). The authors thank the Bloomberg-Kimmel Institute for Cancer Immunotherapy for support and thank the Johns Hopkins University for support from a Discovery Award. DRW thanks the NSF for a Graduate Research Fellowship (DGE-0707427). YJK thanks the Baker Lab for support.
- 1
These authors contributed equally to this work.